A well-known natural product XPO1-specific inhibitor, Leptomycin, LMB, possesses strong anti-tumor activity in vitro, but phase I trials of LMB were discontinued because of its toxicity and lack of apparent efficacy in the tolerable dose range. The gene discussed is XPO1; the disease is neoplasm.